Neurocrine Biosciences (NBIX) has drawn fresh attention after announcing a Phase 1 first in human study of NBIP 1968, a triple agonist candidate aimed at obesity treatment and intended for once weekly subcutaneous dosing.

The Phase 1 obesity study comes on the heels of Neurocrine Biosciences reporting higher second quarter and half year revenue and earnings for 2026, as well as a recent US$742m shelf registration related to an employee stock offering. The share price is at US$163.41, with a 90 day share price return of 4.88% and year to date share price return of 16.22%. The 1 year total shareholder return of 31.80% and 5 year total shareholder return of 81.20% point to momentum that has built over a longer period despite a softer 30 day share price return.

If this obesity update has you thinking about where else growth and AI meet in healthcare, it could be worth scanning 43 healthcare AI stocks as a starting list of ideas.

Neurocrine Biosciences now sits at US$163.41 after a strong run and fresh attention on its obesity portfolio. Does that recent move already reflect the progress, or does the current valuation still leave room before waiting makes sense?

Most Popular Narrative: 23.3% Undervalued

The most followed Neurocrine Biosciences narrative points to a fair value of about $213 per share compared with the current $163.41, which implies investors are weighing strong commercial execution against pipeline and pricing questions.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion. Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides) and a strong preclinical pipeline allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Curious what sits behind that higher fair value for Neurocrine Biosciences. The narrative leans heavily on compounding revenue, expanding margins, and a richer pipeline contribution. The valuation hinges on how far those trends can run and what multiple investors might accept on the other side.

Result: Fair Value of $213.13 (UNDERVALUED)

However, for Neurocrine Biosciences, the story can change quickly if payer pushback on INGREZZA pricing worsens or key late stage CNS trials disappoint.

Next Steps

If the mix of pipeline potential and current pricing questions around Neurocrine Biosciences leaves you undecided, act while the data is fresh and test the thesis yourself. To see what rewards other investors are focusing on, review the 4 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

Do not stop with a single stock. Broaden your watchlist using focused screeners that surface different types of opportunities before the next move gets fully priced in.

• Spot potential value opportunities early by scanning 52 high quality undervalued stocks, which combine quality fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your defensive side by reviewing 83 resilient stocks with low risk scores, which highlight companies with more resilient risk scores for steadier portfolio anchors.
• Hunt for underfollowed opportunities through the screener containing 21 high quality undiscovered gems, which pull together stocks with strong fundamentals but less crowded attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.